Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 1
1979 2
1980 2
1981 3
1982 4
1983 13
1984 13
1985 17
1986 21
1987 14
1988 34
1989 45
1990 75
1991 52
1992 86
1993 86
1994 122
1995 113
1996 105
1997 150
1998 133
1999 141
2000 143
2001 235
2002 282
2003 278
2004 351
2005 321
2006 331
2007 300
2008 285
2009 298
2010 385
2011 395
2012 407
2013 444
2014 487
2015 520
2016 549
2017 500
2018 477
2019 396
2020 483
2021 543
2022 659
2023 648
2024 206

Text availability

Article attribute

Article type

Publication date

Search Results

10,299 results

Results by year

Filters applied: . Clear all
Page 1
The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C. Herbst RS, et al. Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. Nature. 2018. PMID: 29364287 Review.
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and mult …
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past t …
Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update.
Jonna S, Subramaniam DS. Jonna S, et al. Discov Med. 2019 Mar;27(148):167-170. Discov Med. 2019. PMID: 31095926 Free article. Review.
The understanding of genetic alterations that drive non-small cell lung cancer (NSCLC) is evolving. As many of these molecularly-defined subtypes are potentially actionable, new strategies in molecular diagnostics and targeted therapies in NSCLC to det …
The understanding of genetic alterations that drive non-small cell lung cancer (NSCLC) is evolving. As many of t …
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L, Askin F, Gabrielson E, Li QK. Osmani L, et al. Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. doi: 10.1016/j.semcancer.2017.11.019. Epub 2017 Nov 26. Semin Cancer Biol. 2018. PMID: 29183778 Free PMC article. Review.
Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have identified different driver gene mutations in the subtypes of non-small cell lung carcinoma (NSCLC). ...In 2015, the World Health Organization (WHO) and …
Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have identified different driver gene mutations in th …
Molecular Pathology of Lung Cancer.
J Saller J, Boyle TA. J Saller J, et al. Cold Spring Harb Perspect Med. 2022 Mar 1;12(3):a037812. doi: 10.1101/cshperspect.a037812. Cold Spring Harb Perspect Med. 2022. PMID: 34751163 Free PMC article. Review.
This overview of the molecular pathology of lung cancer includes a review of the most salient molecular alterations of the genome, transcriptome, and the epigenome. ...Moreover, this work describes how the evolving field of molecular pathology refines the understanding of …
This overview of the molecular pathology of lung cancer includes a review of the most salient molecular alterations of the genome, tr …
Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
Pennell NA, Arcila ME, Gandara DR, West H. Pennell NA, et al. Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542. doi: 10.1200/EDBK_237863. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099633 Free article. Review.
Over the last decade, the treatment of patients with advanced non-small cell lung cancer (NSCLC) has become reliant on tissue and/or blood biomarkers to help guide treatment decisions. ...
Over the last decade, the treatment of patients with advanced non-small cell lung cancer (NSCLC) has become reli …
ROS1 [corrected].
Pal P, Khan Z. Pal P, et al. J Clin Pathol. 2017 Dec;70(12):1001-1009. doi: 10.1136/jclinpath-2016-204244. Epub 2017 Sep 13. J Clin Pathol. 2017. PMID: 28903995 Review.
ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal …
ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell …
Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.
Kazdal D, Hofman V, Christopoulos P, Ilié M, Stenzinger A, Hofman P. Kazdal D, et al. Genes Chromosomes Cancer. 2022 May;61(5):244-260. doi: 10.1002/gcc.23022. Epub 2022 Jan 22. Genes Chromosomes Cancer. 2022. PMID: 34997651 Review.
Based on superior efficacy and tolerability, targeted therapy is currently preferred over chemotherapy and/or immunotherapy for actionable gene fusions that occur in late-stage non-small cell lung carcinoma (NSCLC). Consequently, current clinica …
Based on superior efficacy and tolerability, targeted therapy is currently preferred over chemotherapy and/or immunotherapy for actionable g …
Genes and pathology of non-small cell lung carcinoma.
Sakashita S, Sakashita M, Sound Tsao M. Sakashita S, et al. Semin Oncol. 2014 Feb;41(1):28-39. doi: 10.1053/j.seminoncol.2013.12.008. Epub 2013 Dec 12. Semin Oncol. 2014. PMID: 24565579 Review.
This has changed dramatically in the last few years, owing to discoveries of genomic aberrations and results of clinical trials of novel and targeted therapies. These discoveries have resulted in a new way of classifying non-small cell lung cancer (NSC …
This has changed dramatically in the last few years, owing to discoveries of genomic aberrations and results of clinical trials of novel and …
Sex steroid metabolism and actions in non-small cell lung carcinoma.
Asavasupreechar T, Chan MSM, Saito R, Miki Y, Boonyaratanakornkit V, Sasano H. Asavasupreechar T, et al. J Steroid Biochem Mol Biol. 2019 Oct;193:105440. doi: 10.1016/j.jsbmb.2019.105440. Epub 2019 Aug 3. J Steroid Biochem Mol Biol. 2019. PMID: 31386890 Review.
Despite recent development in targeted therapies, lung cancer still remains the leading cause of cancer death. Therefore, a better understanding of its pathogenesis and progression could contribute to improving the eventual clinical outcome of the patients. Results of rece …
Despite recent development in targeted therapies, lung cancer still remains the leading cause of cancer death. Therefore, a better un …
A review on engineered magnetic nanoparticles in Non-Small-Cell lung carcinoma targeted therapy.
Ngema LM, Adeyemi SA, Marimuthu T, Choonara YE. Ngema LM, et al. Int J Pharm. 2021 Sep 5;606:120870. doi: 10.1016/j.ijpharm.2021.120870. Epub 2021 Jul 8. Int J Pharm. 2021. PMID: 34245844 Review.
There are growing appeals forthe design of efficacious treatment options for non-small-cell lung carcinoma (NSCLC) as it accrues to ~ 85% cases of lung cancer. ...
There are growing appeals forthe design of efficacious treatment options for non-small-cell lung carcinoma …
10,299 results
You have reached the last available page of results. Please see the User Guide for more information.